Aspirin therapy in primary cardiovascular disease prevention: A position paper of the european society of cardiology working group on thrombosis

Journal of the American College of Cardiology

Volumn 64, Issue 3, 2014, Pages 319-327

  Halvorsen, Sigrun ^a   Andreotti, Felicita ^b   Ten Berg, Jurriën M ^c   Cattaneo, Marco ^d   Coccheri, Sergio ^e   Marchioli, Roberto ^f   Morais, João ^g   Verheugt, Freek W A ^f   De Caterina, Raffaele ^h  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b CATHOLIC UNIVERSITY   (Italy)

^c ST ANTONIUS HOSPITAL   (Netherlands)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f Consorzio Mario Negri Sud Mozzagrogna Chieti ^*  (Netherlands)

^g Hospital Santo Andre   (Portugal)

^h UNIVERSITY OF CHIETI   (Italy)

Author keywords

aspirin; bleeding; cancer; death; myocardial infarction; primary prevention

Indexed keywords

ACETYLSALICYLIC ACID;

BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; MEDICAL SOCIETY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; THROMBOSIS; ACUTE HEART INFARCTION; ARTICLE; CANCER PREVENTION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; HEART PROTECTION; LOW DRUG DOSE; META ANALYSIS (TOPIC); PRACTICE GUIDELINE; PRIMARY PREVENTION;

ASPIRIN; BLEEDING; CANCER; DEATH; MYOCARDIAL INFARCTION; PRIMARY PREVENTION;

ASPIRIN; CARDIOLOGY; CARDIOVASCULAR DISEASES; EUROPE; HUMANS; PRIMARY PREVENTION; SOCIETIES, MEDICAL; THROMBOSIS;

EID: 84904548892     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.03.049     Document Type: Review

References (52)

1. Leibniz G. New Essays on Human Understanding. Book IV, 16. 1703.
2. P. Libby, and P. Theroux Pathophysiology of coronary artery disease Circulation 111 2005 3481 3488
3. P. Libby The molecular mechanisms of the thrombotic complications of atherosclerosis J Intern Med 263 2008 517 527
4. C.W. Hamm, J.P. Bassand, and S. Agewall et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the Management of Acute Coronary Syndromes (ACS) in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) Eur Heart J 32 2011 2999 3054
5. P.G. Steg, S.K. James, and D. Atar et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Eur Heart J 33 2012 2569 2619
6. C. Baigent, L. Blackwell, and R. Collins et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 2009 1849 1860
7. J. Perk, G. De Backer, and H. Gohlke et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Eur Heart J 33 2012 1635 1701
8. P.O. Vandvik, A.M. Lincoff, and J.M. Gore et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th edition: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e637S e668S
9. D.C. Goff Jr., D.M. Lloyd-Jones, and G. Bennett et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 2014 2935 2959
10. R. Peto, R. Gray, and R. Collins et al. Randomised trial of prophylactic daily aspirin in British male doctors Br Med J 296 1988 313 316
11. P.M. Ridker, N.R. Cook, and I.M. Lee et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women N Engl J Med 352 2005 1293 1304
12. Primary Prevention Project Investigators Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project Lancet 357 2001 89 95
13. Steering Committee of the Physicians' Health Study Research Group Final report on the aspirin component of the ongoing Physicians' Health Study N Engl J Med 321 1989 129 135
14. The Medical Research Council's General Practice Research Framework Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk Lancet 351 1998 233 241
15. L. Hansson, A. Zanchetti, and S.G. Carruthers et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial Lancet 351 1998 1755 1762
16. H. Ogawa, M. Nakayama, and T. Morimoto et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial JAMA 300 2008 2134 2141
17. F.G. Fowkes, J.F. Price, and M.C. Stewart et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial JAMA 303 2010 841 848
18. J. Belch, A. MacCuish, and I. Campbell et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial BMJ 337 2008 a1840
19. F.W.A. Verheugt Aspirin, the poor man's statin? Lancet 351 1998 227 228
20. A.A. Bartolucci, M. Tendera, and G. Howard Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin Am J Cardiol 107 2011 1796 1801
21. N. Raju, M. Sobieraj-Teague, and J. Hirsh et al. Effect of aspirin on mortality in the primary prevention of cardiovascular disease Am J Med 124 2011 621 629
22. J.S. Berger, A. Lala, and M.J. Krantz et al. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials Am Heart J 162 2011 115 124 e2
23. S.R. Seshasai, S. Wijesuriya, and R. Sivakumaran et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials Arch Intern Med 172 2012 209 216
24. F. Perego, and G. Casazza Why meta-analyses on the same topic lead to different conclusions? Intern Emerg Med 7 2012 381 383
25. P. Sutcliffe, M. Connock, and T. Gurung et al. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews Health Technol Assess 17 2013 1 253
26. Jones WS, Schmit KM, Vemulapalli S, et al. Treatment Strategies for Patients With Peripheral Artery Disease. Rockville, MD: 2013.
27. L. Robertson, E. Atallah, and G. Stansby Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic aneurysm Cochrane Database Syst Rev 1 2014 CD010447
28. J. He, P.K. Whelton, and B. Vu et al. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials JAMA 280 1998 1930 1935
29. M. Cattaneo Haemorrhagic stroke during anti-platelet therapy Eur J Anaesthesiol Supplement 42 2008 12 15
30. Antiplatelet Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
31. M. Pignone, M.J. Alberts, and J.A. Colwell et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation Circulation 121 2010 2694 2701
32. N. Sarwar, P. Gao, and S.R. Seshasai et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies Lancet 375 2010 2215 2222
33. S.M. Haffner, S. Lehto, and T. Ronnemaa et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 1998 229 234
34. U. Bulugahapitiya, S. Siyambalapitiya, and J. Sithole et al. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis Diabet Med 26 2009 142 148
35. ETDRS Investigators Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14 JAMA 268 1992 1292 1300
36. G. De Berardis, M. Sacco, and G.F. Strippoli et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials BMJ 339 2009 b4531
37. C. Zhang, A. Sun, and P. Zhang et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis Diabetes Res Clin Pract 87 2010 211 218
38. A.D. Calvin, N.R. Aggarwal, and M.H. Murad et al. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes Diabetes Care 32 2009 2300 2306
39. P.M. Rothwell, F.G. Fowkes, and J.F. Belch et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials Lancet 377 2011 31 41
40. E.J. Mills, P. Wu, and M. Alberton et al. Low-dose aspirin and cancer mortality: a meta-analysis of randomized trials Am J Med 125 2012 560 567
41. P.M. Rothwell, J.F. Price, and F.G. Fowkes et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials Lancet 379 2012 1602 1612
42. N.R. Cook, I.M. Lee, and S.M. Zhang et al. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial Ann Intern Med 159 2013 77 85
43. M. Nelson, C. Reid, and L. Beilin et al. Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE) Drugs Aging 20 2003 897 903
44. T. Teramoto, K. Shimada, and S. Uchiyama et al. Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events Am Heart J 159 2010 361 369 e4
45. G. De Berardis, M. Sacco, and V. Evangelista et al. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D) Trials 8 2007 21
46. C.M. Reid, E. Storey, and T.Y. Wong et al. Aspirin for the prevention of cognitive decline in the elderly: rationale and design of a neuro-vascular imaging study (ENVIS-ion) BMC Neurol 12 2012 3
47. S. Juul-Moller, N. Edvardsson, and B. Jahnmatz et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris Lancet 340 1992 1421 1425
48. C. Patrono Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither? Eur Heart J 34 2013 3403 3411
49. S.J. Connolly, J.W. Eikelboom, and J. Ng et al. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable Ann Intern Med 155 2011 579 586
50. U.S. Preventive Services Task Force Aspirin for the primary prevention of cardiovascular events: recommendation and rationale Ann Intern Med 136 2002 157 160
51. T.A. Pearson, S.N. Blair, and S.R. Daniels et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee Circulation 106 2002 388 391
52. M. Volpe, A. Battistoni, and G. Tocci et al. Cardiovascular risk assessment beyond Systemic Coronary Risk Estimation: a role for organ damage markers J Hypertens 30 2012 1056 1064